Related Experiment Videos
[A case of interferon beta-induced pneumonia]
H Kourakata1, Y Tanabe, O Mikami
1Department of Medicine, Nagaoka Red Cross Hospital, Niigata, Japan.
Insights
This case report details a rare instance of interferon beta-induced pneumonia in a glioblastoma patient. Prompt steroid treatment resolved the severe lung complications, highlighting the need for vigilance with this therapy.
Area of Science:
- Oncology
- Pulmonology
- Pharmacology
Background:
- Cerebral glioblastoma treatment often involves a combination of chemotherapy, radiation, and immunotherapy.
- Interferon beta is used in some oncological treatments, but its pulmonary side effects are infrequently reported.
- Nimustine hydrochloride (ACNU) and brain irradiation are standard glioblastoma therapies.
Observation:
- A 58-year-old male treated for glioblastoma developed fever, cough, and dyspnea one month after nimustine hydrochloride, interferon beta, and brain irradiation.
- Chest imaging revealed diffuse ground-glass opacities, and bronchoalveolar lavage showed lymphocytic and neutrophilic alveolitis with a decreased CD4/8 ratio.
- Symptoms and radiographic findings worsened progressively, indicating a severe pulmonary reaction.
Findings:
- The patient's condition rapidly improved after discontinuing interferon beta and initiating high-dose steroid therapy.
- Bronchoalveolar lavage results indicated an inflammatory pneumonitis consistent with a drug-induced reaction.
- The clinical presentation and resolution strongly suggest interferon beta as the causative agent for the pneumonia.
Implications:
- This case underscores the potential for rare but severe pulmonary toxicity from interferon beta, even at doses used adjunctively in oncology.
- Early recognition and cessation of interferon beta, coupled with prompt corticosteroid treatment, are crucial for managing interferon beta-induced pneumonia.
- Further investigation into the mechanisms and risk factors for interferon beta-associated lung injury is warranted to improve patient safety.
Abstract:
A 58-year-old man had been treated with one intravenous injection of 120 mg of nimustine hydrochloride (ACNU), ten thrice-weekly doses of 3,000,000 U of interferon beta, and brain irradiation for cerebral glioblastoma. One month later he had fever, appetite loss, a productive cough and dyspnea. Chest radiography and CT showed diffuse, nonsegmental ground glass opacity in both lung fields. Hypoxemia and lung shadows were exacerbated day by day. Bronchoalveolar lavage revealed an increases in the total cell count and the percentages of lymphocytes and neutrophils, and a decrease of the CD 4/8 ratio. Interferon beta therapy was stopped, and steroid pulse therapy and prednisolone 40 mg administration were initiated. The symptoms, hypoxemia and lung shadows quickly improved. Reported cases of interferon beta-induced pneumonia are rare.